A Trial of Tocilizumab in ALS Subjects (TCZALS-001)
A Phase 2 Randomized, Placebo Controlled Trial of Tocilizumab in ALS Subjects
Sponsor: ALS Association
Listed as NCT02469896, this PHASE2 trial focuses on ALS and Amyotrophic Lateral Sclerosis and remains completed. Sponsored by ALS Association, it has been updated 10 times since 2015, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Aug 2018 — Jan 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Dec 2017 — May 2018 [monthly]
Recruiting PHASE2
-
Feb 2017 — Dec 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Nov 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ALS Association
- Barrow Neurological Foundation
- Barrow Neurological Institute
- Genentech, Inc.
- Massachusetts General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .